Company / PP&E (Net)
Crinetics Pharmaceuticals, Inc. PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$14.3M
FY2025
5-year range
$2.8M / $14.3M
FY2021-FY2025
Trend
+18.5%
vs FY2024
Sector context
#87 of 193
Health Care
What the data says
At $14M, Crinetics Pharmaceuticals, Inc.'s pp&e (net) ranks #87 of 193 in the Health Care sector. PP&E (Net) has increased for 4 consecutive years, from $3M in FY2021 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +35.1%.
Improved from $11M to $14M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +59.9%
- 5-Year CAGR
- +35.1%
- 10-Year CAGR
- -
Sector benchmark
#87 of 193 in Health CareTop 45% of 193This company $14.3M Sector average $777.6M
▼
-98.2% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s pp&e (net) has grown for 4 consecutive years.
- 5-year CAGR of +35.1%, indicating consistent growth.
- In FY2025, pp&e (net) increased 18.5% year-over-year.
- Ranks #87 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.3M | +18.5% |
| FY2024 | $12.1M | +10.9% |
| FY2023 | $10.9M | +210.9% |
| FY2022 | $3.5M | +23.9% |
| FY2021 | $2.8M | -11.2% |
| FY2020 | $3.2M | -19.4% |
| FY2019 | $3.9M | -6.8% |
| FY2018 | $4.2M | +958.0% |
| FY2017 | $400.0K | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026